Here are four key statistics:
1. Through 2020, orphan drugs’ annual sales are likely to increase 12 percent each year.
2. The average annual price tag for orphan drugs totaled $111,820 in 2014. Comparatively, mainstream drugs cost $23,331, on average, that year.
3. Excluding genetics, estimates expect global orphan drug sales to comprise slightly more than 20 percent of all drug sales.
4. The Department of Health sent a report to Congress in December 2016 which found orphan drugs cost $1 billion to develop, compared to $2.6 billion for mass market drugs.
More articles on quality & infection control:
North America leads global infection control market with 39.5% market share: 5 takeaways
ASC Quality Collaboration report: 9 key benchmarks from Q3 2016
Trump’s take on pharmaceutical companies: ‘Getting away with murder’
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.